The latest interim data from XPAND, AirXpanders Inc.’s U.S.-based, head-to-head pivotal study of its new, needle-free, patient-controlled tissue expansion system

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

New User Registration
 
 
 
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field